Form 4: Amgen SVP Rachna Khosla Reports Equity Grant

Amgen SVP of Business Development Rachna Khosla received a grant of 500 restricted stock units and 3,266 stock options.

Summary

• Rachna Khosla, SVP of Business Development at Amgen, was granted 500 Restricted Stock Units (RSUs) on May 5, 2026.
• The reporting person was also granted 3,266 non-qualified stock options with an exercise price of $329.59.
• A total of 79 shares were withheld on May 6, 2026, to satisfy tax obligations related to the vesting of equity awards.
• Following these transactions, the reporting person holds 8,487 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no material impact on the company's financial outlook.

Positives

• The equity grants align the interests of the SVP of Business Development with long-term shareholder value.
• The vesting schedule of four equal annual installments encourages long-term retention of key leadership.

Negatives

• The withholding of 79 shares for tax purposes represents a minor reduction in direct ownership.

Risks

• The value of the granted stock options is subject to market volatility and the future performance of Amgen common stock.

Future Outlook

The equity grants are subject to a four-year vesting schedule, with 25% vesting annually starting May 5, 2027, indicating a long-term commitment to the company.

Industry Context

StockSavvy.ai notes that routine equity grants to senior executives are standard corporate governance practices in the biopharmaceutical industry to ensure leadership alignment with shareholder interests.

Comparison to Industry Standards

• The use of four-year vesting schedules for executive equity is consistent with standard compensation practices among large-cap pharmaceutical companies like Pfizer, Merck, and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as these are standard executive compensation grants.

Next Steps

• Vesting of the first 25% of the RSU and option grants on May 5, 2027.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Incentive Plan, Business Development